• Affiliate Professor, Global Health
  • Senior Vice President, Drug Discovery, IDRI

Infectious Disease Research Institute
1616 Eastlake Avenue E
Suite 400
Seattle, WA 98102
United States

Phone Number: 
206-858-6074
Select from the following:
Biography 

Tanya Parish is the Senior Vice President of Drug Discovery at IDRI where she heads the TB Discovery Research group. Her work focuses on the discovery of new drugs that are effective at curing drug-sensitive and drug-resistant tuberculosis with the added goal of shortening the time it takes to cure disease. This encompasses a range of early stage drug discovery including drug target identification and validation, high throughput screening and medicinal chemistry. In addition, her group works to understand the pathogenic mechanisms and basic biology of the global pathogen Mycobacterium tuberculosis and using this information to inform drug discovery.

Education 
  • PhD (National Institute For Med Res (UK))
  • BSc (University of London (UK))
Country Affiliations 
Health Topics 
  • Infectious Diseases
  • Leishmaniasis
  • Pathogenesis
  • TB
DGH Centers, Programs and Initiatives and Affiliated Organizations 
Publications 

Imidazopyridine compounds inhibit mycobacterial growth by depleting ATP levels. 2018. T. O'Malley, T. Alling, J. Early, H. Wescott, A.Kumar, G. Moraski, M.J. Miller, T. Masquelin, P.A. Hipskind, and T. Parish. Antimicrob. Agents Chemother. 62: e02439-17 PMID: 29632008 doi: 10.1128/AAC.02439-17

Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis. 2018. M.A. Martinez-Grau, I.C. Gonzalez Valcarcel, J.V Early, R.K. Gessner, C.S. de Melo, E.M. Martin de la Nava, A. Korkegian, Y.Ovechkina, L. Flint, A. Gravelle, J.W. Cramer, P.V. Desai, L.J. Street, J. Odingo, T. Masquelin, K. Chibale, T. Parish. Bioorg Med Chem Lett. 28: 1758-1764. PMID: 29680666 DOI: 10.1016/j.bmcl.2018.04.028

Combinations of respiratory chain inhibitors have enhanced bactericidal activity against Mycobacterium tuberculosis. 2017. B.J. Berube and T. Parish. Antimicrob. Agents Chemother. 62: e01677-17. PMID: 29061760 PMCID: PMC5740367

Improved phenoxyalkylbenzimidazoles with activity against Mycobacterium tuberculosis appear to target QcrB. 2017. N. S. Chandrasekara, B. Berube, G. Shetye, S. Chettiar, T. O’Malley, A. Manning, L. Flint, D. Awasthi, T. Ioerger, J. Sacchettini, T. Masquelin, P. Hipskind, J. Odingo and T. Parish. ACS Inf Dis. 3: 898-916. PMCID: 5727484

Imidazoles induce reactive oxygen species in Mycobacterium tuberculosis which is not associated with cell death. 2017. H.A. Howell Wescott, D.M. Roberts, C.L. Allebach, R. Kokoczka and T. Parish. ACS Omega.2: 41-51. PMCID# PMC5286457